2018

26 Nov 2018
Golden Meditech Announces FY2018/2019 Interim Results
Hong Kong, 26 November 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces today its interim results for the six months ended 30 September 2018 (the "Reporting Period").
27 Jun 2018
Golden Meditech Announces FY2017/2018 Annual Results
Hong Kong, 27 June 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801)("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces today its annual results for the year ended 31 March 2018 (the "Year" or "FY2017/2018").
16 Apr 2018
Golden Meditech's Associate, Cellenkos Names Alick Sun As Corporate & Business Development SVP
Hong Kong, 16 April 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announced that its associate, Cellenkos, Inc. ("Cellenkos") has appointed Alick Sun as Senior Vice President ("SVP") for Corporate & Business Development of Cellenkos, further strengthening Cellenkos' executive team as Cellenkos continues reinforcing the foundation for long-term growth. He will be responsible for leading all business and corporate development activities of Cellenkos. Alick Sun is the SVP of Golden Meditech, and holds a concurrent position in Cellenkos. Golden Meditech is a major shareholder of Cellenkos.
19 Mar 2018
Golden Meditech's Largest Shareholder Further Increased Shareholdings
Hong Kong, 19 March 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, is pleased to announce that the Company's largest shareholder Mr. Kam Yuen, Chairman and Chief Executive Officer of the Group, has further increased his shareholding in Golden Meditech by acquiring a total of 9,300,000 shares through Bio Garden Inc., his family-owned entity, on 15 March 2018 and 19 March 2018 respectively. The new shares were acquired at the price ranging from HK$0.91 to HK$0.93 per share.
14 Mar 2018
Golden Meditech's Largest Shareholder Acquired Additional 9,068,000 Shares
Hong Kong, 14 March 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, is pleased to announce that the Company's largest shareholder Mr. Kam Yuen, Chairman and Chief Executive Officer of the Group, has further increased his shareholding in Golden Meditech by acquiring a total of 9,068,000 shares through Bio Garden Inc., his family-owned entity, on 9 March 2018 and 13 March 2018 respectively. The new shares were acquired at the price ranging from HK$0.92 to HK$0.96 per share. Upon the acquisition and the cancellation of the repurchased Taiwan depository receipts shares, Mr. Kam Yuen and his concert parties hold an aggregate of 2,096,111,560 shares, representing approximately 71.86% of the issued share capital of the Company.
28 Feb 2018
Golden Meditech's Subsidiary Completes Acquisition of 50% Equity Interest in ASA
Hong Kong, 28 February 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, announces that Golden Meditech K.K., an indirect wholly-owned subsidiary of the Company, has completed the acquisition of 50% equity interest in ASA Asset Management Co., Ltd. ("ASA"). The transaction was announced by the Company earlier on December 11, 2017.
26 Feb 2018
Golden Meditech Lays Out Strategic Plan across the Value Chain in the Emerging Biomedical Industry
Hong Kong, 26 February 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, is pleased to announce that Shanghai GM Diagnosis Co., Ltd.* ("GM Diagnosis"), a subsidiary of the Group, has obtained a Practicing License for Medical Institution* (醫療機構執業許可證) to provide molecular genetic pathology services. This marks another major development in the Group's precision medicine field, following its strategic investment in immunotherapy business in the United States of America ("U.S.A.") in 2017, as well as setting up its two subsidiaries, namely Shanghai GM LifeBank Co., Ltd.* ("GM LifeBank") and Shanghai GM BioX Co., Ltd.* ("GM BioX"). GM LifeBank provides cell and tissue storage services, while GM BioX conducts biotechnology research and development. Both obtained relevant operational approvals in 2014 and 2015, respectively.
13 Feb 2018
Golden Meditech Declares a Special Dividend to Shareholders
Hong Kong, 13 February 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801)(the "Company"), a leading integrated healthcare enterprise in China, is pleased to announce that the board of directors of the Company (the "Board") declares a special cash dividend of HK$0.30 per share in acknowledgment of the continuous support and trust from its shareholders, following the completion of the sale of equity interest in China Cord Blood Corporation. Additionally, the Company is proactively looking for investment opportunities, if there are no suitable investment projects, the Board may consider declaring further special dividend.
7 Feb 2018
Golden Meditech Announces FDA Registration of GMP Manufacturing Facility by Its Associate, Cellenkos, Inc.
Hong Kong, 7 February 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801)("Golden Meditech"), a leading integrated healthcare enterprise in China, announces that its associate, Cellenkos, Inc. ("Cellenkos") successfully registered its's stand-alone, manufacturing facility as good manufacturing practice ("GMP") compliant with United States Food and Drug Administration ("FDA"). Cellenkos is a clinical-stage biotechnology company focused on developing universal donor cell therapeutics derived from cord blood for the treatment of autoimmune diseases and inflammatory conditions.
4 Feb 2018
Golden Meditech Acquires 16.14% Interest of Ying Peng Hui Kang Fund
Hong Kong, 4 February 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that Golden Meditech Technology (Shanghai) Company Limited* (金衛醫療科技(上海)有限公司), a wholly-owned subsidiary of the Company, acquires 16.14% interest in Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership)* (南京盈鹏蕙康醫療產業投資合夥企業(有限合夥)) ("Ying Peng Hui Kang Fund") as a limited partner by entering into a transfer agreement with, among others, Hengqin Long Xi II Investment Center (Limited Partnership)* (橫琴隆璽貳號投資中心(有限合夥)) ("Hengqin Investment") for a total cash consideration which is equivalent to the initial capital contribution in the amount of RMB1.060 billion made by Hengqin Investment and a 9% annual return rate (the total consideration shall not be more than approximately RMB1.127 billion in any event) (the "Acquisition").
1 Feb 2018
Golden Meditech Announces Close of Repurchase of TDR for the Delisting of TDR on TWSE
Hong Kong, 1 February 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801)(the "Company"), a leading integrated healthcare enterprise in China, announces today the TDR repurchase period is closed on January 31, 2018, regarding the proposed voluntary delisting of the Taiwan depository receipts ("TDR") from the Taiwan Stock Exchange Corporation. The Company is obliged to repurchase approximately 49.21 million outstanding TDRs at a total consideration of approximately NT$219 million (approximately HK$58.71 million).
31 Jan 2018
Golden Meditech Completes Sale of Equity Interest in China Cord Blood Corporation
Hong Kong, 31 January 2018 - Golden Meditech Holdings Limited (SEHK stock code: 00801)(the "Company"), a leading integrated healthcare enterprise in China, is pleased to announce that the sale of 65.4% of the issued share capital of China Cord Blood Corporation to Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership)* (南京盈鹏蕙康醫療產業投資合夥企業(有限合夥)) has been completed.

Please download the latest "Acrobat Reader" to view the PDF.

Back to top